157033-23-3

Usage

Uses

Used in Pharmaceutical Industry:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as an intermediate in the synthesis of various pharmaceutical compounds for its reactivity and ability to form new organic compounds.
Used in Agrochemical Industry:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as a precursor in the production of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Research and Development:
(2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE is used as a reactive intermediate in research and development settings for the synthesis of novel organic compounds and the study of chemical reactions.
Safety Precautions:
Due to its reactivity and potential hazards, (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE should be handled with care, and proper safety precautions should be taken when working with (2,5-DIFLUORO-PHENYL)-ACETYL CHLORIDE.

Upstream product

• 85068-27-5 2,5-difluorophenylacetic acid 

Downstream Products

• 764667-66-5 5-[1-hydroxy-2-(2,5-difluorophenyl)ethylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 1258517-58-6 (Z)-ethyl 2-amino-2-(2-(2,5-difluorophenyl)acetoxyimino)acetate 
• 486459-98-7 (3R)-3-[(1,1-dimethylethoxycarbonyl)amino]-4-(2,5-difluorophenyl)butanoic acid 
• 767352-25-0 N-benzyloxy-4-(2,5-difluorophenyl)-3(S)-hydroxybutanamide 
• 767352-26-1 N-benzyloxy-4(R)-[1-methyl-(2,5-difluorobenzyl)]-2-oxoazetidine 
• 848667-51-6 (3S)-4-(2,5-difluorophenyl)-3-hydroxybutanoic acid 
• 848667-53-8 (R)-3-Amino-4-(2,5-difluoro-phenyl)-butyric acid methyl ester 
• 848667-50-5 methyl (3S)-4-(2,5-difluorophenyl)-3-hydroxybutanoate 
• 767352-24-9 methyl 4-(2,5-difluorophenyl)-3-oxobutanoate 

Relevant academic research and scientific papers

Phosphonic acid analogs of fluorophenylalanines as inhibitors of human and porcine aminopeptidases N: Validation of the importance of the substitution of the aromatic ring

A library of phosphonic acid analogs of phenylalanine substituted with fluorine, chlorine and trifluoromethyl moieties on the aromatic ring was synthesized and evaluated for inhibitory activity against human (hAPN) and porcine (pAPN) aminopeptidases. Fluorogenic screening indicated that these analogs are micromolar or submicromolar inhibitors, both enzymes being more active against hAPN. In order to better understand the mode of the action of the most active compounds, molecular modeling was used. It confirmed that aminophosphonic portion of the enzyme is bound nearly identically in the case of all the studied compounds, whereas the difference in activity results from the placement of aromatic side chain of an inhibitor. Interestingly, both enantiomers of the individual compounds are usually bound quite similarly.

The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing

New drugs for neglected tropical diseases such as human African trypanosomiasis (HAT) are needed, yet drug discovery efforts are not often focused on this area due to cost. Target repurposing, achieved by the matching of essential parasite enzymes to those human enzymes that have been successfully inhibited by small molecule drugs, provides an attractive means by which new drug optimization programs can be pragmatically initiated. In this report we describe our results in repurposing an established class of human Aurora kinase inhibitors, typified by danusertib (1), which we have observed to be an inhibitor of trypanosomal Aurora kinase 1 (TbAUK1) and effective in parasite killing in vitro. Informed by homology modeling and docking, a series of analogs of 1 were prepared that explored the scope of the chemotype and provided a nearly 25-fold improvement in cellular selectivity for parasite cells over human cells.

INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES

This invention provides novel compounds and the novel compounds for use as a medicine, more in particular for the prevention or treatment of neurodegenerative disorders, more specifically certain neurological disorders, such as disorders collectively known as tauopathies, and disorders characterised by cytotoxic α-synuclein amyloidogenesis. The present invention also relates to the use of said novel compounds for the manufacture of medicaments useful for treating such neurodegenerative disorders. The present invention further relates to pharmaceutical compositions including said novel compounds and to methods for the preparation of said novel compounds.

Synthesis of a β-amino acid pharmacophore via a β-lactam intermediate

(Chemical Equation Presented) A stereoselective synthesis of (R)-β-amino acid 1 via a β-lactam intermediate is discussed.